{'fraction_non_alphanumeric': 0.015691868758915834, 'fraction_numerical': 0.018544935805991442, 'mean_word_length': 5.267857142857143, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Using Antiretrovirals to Prevent HIV: Implications of the outcome of the CAPRISA 004 tenofovir-gel microbicide trial

The results of the CAPRISA 004 trial testing tenofovir gel as a vaginal microbicide will be announced on Tuesday 20 July at 1pm at AIDS 2010, Vienna. The Tuesday evening satellite aims to further explore the results with an in-depth discussion engaging the study’s two principal investigators. Leading scientists and advocates will debate the findings and their implications on the international HIV-biomedical prevention research agenda. They will explore the potential impact of microbicides on the HIV epidemic and ask the important question: what do these results mean for women?